The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura01.27.21
A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
Lilly expands BLAZE-4 trial to evaluate bamlanivimab with VIR-7831, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein.